Moreover, ccRCC with sarcomatoid features are more sensitive to immune checkpoint inhibitors than to VEGF(R) inhibitors, and express higher levels of the programmed death ligand-I (PD-L1) protein. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.